DelveInsight’s, Metastatic Merkel Cell Carcinoma Pipeline Insight” report provides comprehensive insights about 13+ companies and 15+ pipeline drugs in Metastatic Merkel Cell Carcinoma pipeline landscape. It covers the Metastatic Merkel Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Merkel Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Metastatic Merkel Cell Carcinoma Pipeline Outlook Report

Key Takeaways from the Metastatic Merkel Cell Carcinoma Pipeline Report

• In May 2025, Medicenna Therapeutics Inc. announced a study drug, MDNA11, long-acting “beta-only” recombinant interleukin-2 (rIL-2). MDNA11 specifically engineered to overcome the shortcomings of rhIL-2 (aldesleukin) by preferentially activating immune effector cells (CD8+ T- and NK cells) responsible for killing cancer cells, with minimal or no stimulation of immunosuppressive Tregs. It is designed to potentially enhance host immune response and fusion to albumin increases the half-life further avoiding frequent dosing required with rhIL-2.
• In April 2025, Aulos Biosciences Inc. announced a Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of AU-007 plus aldesleukin is determined, AU-007 plus aldesleukin will also be administered with avelumab or nivolumab.
• DelveInsight’s Metastatic Merkel Cell Carcinoma Pipeline analysis depicts a robust space with 13+ active players working to develop 15+ pipeline treatment therapies.
• The leading Metastatic Merkel Cell Carcinoma Companies such as Incyte Corporation, Merck, Pfizer, Millennium Pharmaceuticals Inc., Novartis Pharmaceuticals, Exelixis, Philogen SpA, Bristol-Myers Squibb, EMD Serono, Exicure Inc, and others.
• Promising Metastatic Merkel Cell Carcinoma Pipeline Therapies such as Retifanlimab, Avelumab, MLN0128, Pasireotide sub-cutaneous formulation, Cabozantinib, Pembrolizumab, and others.

Learn how leading Metastatic Merkel Cell Carcinoma Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Metastatic Merkel Cell Carcinoma Clinical Trials Assessment

Metastatic Merkel Cell Carcinoma Emerging Drugs

• Retifanlimab: Incyte

Retifanlimab (formerly INCMGA0012), an investigational intravenous PD-1 inhibitor, is currently under evaluation in registration-directed trials as a monotherapy for patients with microsatellite instability-high endometrial cancer, Merkel cell carcinoma and squamous cell carcinoma of the anal canal (SCAC); and in combination with platinum-based chemotherapy for patients with non-small cell lung cancer and SCAC.

The Metastatic Merkel Cell Carcinoma pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Merkel Cell Carcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Merkel Cell Carcinoma Treatment.
• Metastatic Merkel Cell Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Metastatic Merkel Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Merkel Cell Carcinoma market.

From early-stage research to late-phase Metastatic Merkel Cell Carcinoma Clinical Trials, our analysis covers key Metastatic Merkel Cell Carcinoma Companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Metastatic Merkel Cell Carcinoma Treatment Drugs

Metastatic Merkel Cell Carcinoma Companies

Incyte Corporation, Merck, Pfizer, Millennium Pharmaceuticals Inc., Novartis Pharmaceuticals, Exelixis, Philogen SpA, Bristol-Myers Squibb, EMD Serono, Exicure Inc and others.

Metastatic Merkel Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous

Metastatic Merkel Cell Carcinoma Products have been categorized under various Molecule types such as

• Small molecule
• Cell Therapy
• Peptides
• Polymer
• Small molecule
• Gene therapy

Stay updated with the latest Metastatic Merkel Cell Carcinoma Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Metastatic Merkel Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Metastatic Merkel Cell Carcinoma Pipeline Report

• Coverage- Global
• Metastatic Merkel Cell Carcinoma Companies– Incyte Corporation, Merck, Pfizer, Millennium Pharmaceuticals Inc., Novartis Pharmaceuticals, Exelixis, Philogen SpA, Bristol-Myers Squibb, EMD Serono, Exicure Inc, and others.
• Metastatic Merkel Cell Carcinoma Pipeline Therapies- Retifanlimab, Avelumab, MLN0128, Pasireotide sub-cutaneous formulation, Cabozantinib, Pembrolizumab, and others.
• Metastatic Merkel Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Metastatic Merkel Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Metastatic Merkel Cell Carcinoma Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Metastatic Merkel Cell Carcinoma Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Metastatic Merkel Cell Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Metastatic Merkel Cell Carcinoma– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Drug name: Company name
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Retifanlimab: Incyte Corporation
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. SO-C101: SOTIO Biotech
15. Drug profiles in the detailed report…..
16. Preclinical Stage Products
17. SNS 401 NG: Sensei Biotherapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Metastatic Merkel Cell Carcinoma Key Companies
21. Metastatic Merkel Cell Carcinoma Key Products
22. Metastatic Merkel Cell Carcinoma- Unmet Needs
23. Metastatic Merkel Cell Carcinoma- Market Drivers and Barriers
24. Metastatic Merkel Cell Carcinoma- Future Perspectives and Conclusion
25. Metastatic Merkel Cell Carcinoma Analyst Views
26. Metastatic Merkel Cell Carcinoma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-merkel-cell-carcinoma-pipeline-insight